Answers are grounded in this paper and cite their sources.
Huntington's disease is a progressive neurodegenerative disorder for which therapies are woefully inadequate and do not prevent inevitable progression. Currently approved therapies are primarily aimed at treating chorea, but do not address the more clinically meaningful motor, behavioral, and cognitive features of the disease. However, there are a number of promising new therapies that are currently being studied in the laboratory, and in the clinic. This article will review the wide variety of therapies currently being tested, the advances in clinical trials and end points, and the many potentially relevant new targets.
No takes yet. Share an insight, caveat, or question.
Kieburtz et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: